Lixivaptan

N/A

Report date: 2022/11/01 20:00:51
NME

Base Information

Drug NameLixivaptan
Drug Alias Name利伐普坦Lixarlixivaptan利赛伐坦利希普坦 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVasopressin V2 receptor antagonists
TargetsVasopressin V2 receptor
Therapy Area/IndicationsHyponatremiaHeart FailurePolycystic Kidney, Autosomal Dominant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[23] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCardiokine IncPalladio Biosciences IncCentessa Pharmaceuticals Plc
Active IndicationsN/A
Inactive IndicationsHyponatremiaHeart FailurePolycystic Kidney, Autosomal Dominant

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG